信得科技递表港交所 2024年收入和利润“双降”

Core Viewpoint - Shandong Xinde Technology Co., Ltd. has submitted its IPO application to the Hong Kong Stock Exchange, aiming to raise funds for R&D, product expansion, capacity enhancement, and working capital [1] Group 1: Company Overview - Founded in 1999, Xinde Technology is a leading animal health company in China, focusing on the R&D, production, and sales of a full range of animal health products, including veterinary biological products, traditional Chinese veterinary medicine, chemical drugs, animal feed, and feed additives [2] - The company ranks ninth among domestic brands in the Chinese animal health market and is among the top three in the poultry veterinary biological products market [2] - Xinde Technology operates four production bases and 34 production lines that comply with veterinary GMP standards [2] Group 2: Financial Performance - For the reporting periods of 2023, 2024, and the first three quarters of 2025, Xinde Technology's revenue primarily came from veterinary biological products, accounting for 63.6%, 64.2%, and 69.1% of total revenue, respectively [3] - The company reported revenues of 985 million yuan, 982 million yuan, and 877 million yuan for the respective years, with profits of 34.76 million yuan, 28.12 million yuan, and 55.67 million yuan [4] - In 2024, the company anticipates a decline in both revenue and profit, with profit expected to drop by approximately 19% compared to 2023 [4] Group 3: Market Challenges - The animal health industry is highly competitive, with over 1,500 veterinary drug manufacturers in China, leading to increased bargaining power among customers [2] - Xinde Technology acknowledges that rising customer bargaining power may negatively impact its profitability [2] - The average selling price of antibody products is expected to decline in 2024, contributing to the anticipated decrease in revenue and profit [4] Group 4: Funding and Valuation - Following the C round of financing, Xinde Technology's post-investment valuation is approximately 1.8 billion yuan, a decrease of 37.5% compared to the valuation after the B round and a share transfer in August 2022 [6] - The company has confirmed government subsidies of approximately 28.7 million yuan for 2024, exceeding its projected profit for that year [4] Group 5: Compliance and Liabilities - Xinde Technology has not fully paid social insurance and housing fund contributions for several employees, with total arrears amounting to approximately 55 million yuan over the reporting periods [7] - The company may face penalties and late fees due to these unpaid contributions [7]